2. What has already been done and how is it related?
• Shared Dialog
• LEO Focus Group
• Industry Partner Program RoundTables
• NAAF Conference where Industry is Present
• Research Summits with Patient Participation
• Publications from our shared dialog
JID Symposium Proceedings
Alopecia Areata is a Medical Disease
Collaboration on
3. What questions still need to be answered?
• Willingness to pay vs. Willingness to Risk
• Natural history of disease
4. What resources are needed?
• Unlimited access to capital and human resources
• NAAF is a small but mighty staff of 8
• With our industry partners – we got this!
5. What can NAAF do to help?
• Opportunities for Dialogue
• Willingness to pay vs. Willingness to Risk
• Information on the continuum of Desires for Treatment and Willingness to Risk
• What treatments are best for which people
• Collaboration on Publication of what we discover through this dialog
• Address psychosocial and emotional impacts - If we achieve acceptance, do we need to treat
the hair?
• Terminology that doesn’t increase stigma AND acknowledges severity of disease impact on QoL
• Communicate back to patient population the value of BioPharma companies bringing resource
to dermatology and Alopecia Areata that is
• beyond the study of a particular type of treatment – other benefits to field in
• chance discoveries that lead to new avenues of inquiry
• even if medication is not appropriate to all.